The company generates renewable energy through wind turbines and engages in the wholesale trading of agricultural and metal commodities.
The company operates in commodity trading and regulated wind energy, neither of which offers a competitive advantage. Low average ROCE of 4.6% confirms the lack of pricing power or cost leadership.
Capital is primarily deployed into low-return inter-corporate loans and investments in struggling subsidiaries like Shree Rama Newsprint. Significant funds are diverted to related parties rather than high-yielding internal growth or shareholder returns.
The investment collapsed as the company's role shifted from a business to a captive financing vehicle for the promoters. Over five years, the capital leakage through unsecured loans to related parties like Bluecraft Agro and the continuous subsidization of the loss-making Shree Rama Newsprint drained the balance sheet. Regulatory pressure from SEBI intensified following previous delisting and market access violations, leading to further sanctions that paralyzed corporate actions. With a negative cash conversion cycle and returns on capital consistently below the cost of debt, the intrinsic value eroded until the market finally priced the entity as a distressed pool of mismanaged assets rather than a going concern.
RichFakir rates Riddhi Siddhi Gluco Biols Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Riddhi Siddhi Gluco Biols Ltd is trading about 67% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Riddhi Siddhi Gluco Biols Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Riddhi Siddhi Gluco Biols Ltd's fair value is about ₹421 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →